Product Description
Mechanisms of Action: ITPRIPL1 Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| BT02 | P1 |
Recruiting |
Oncology Solid Tumor Unspecified |
2024-12-31 |
|
| CTR20240083 | N/A |
Unknown Status |
Oncology Solid Tumor Unspecified |
None |